Artelo Biosciences
ARTL
9 hedge funds and large institutions have $464K invested in Artelo Biosciences in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 8 closing their positions.
5% more capital invested
Capital invested by funds: $443K → $464K (+$21.2K)
0.25% more ownership
Funds ownership: 0.01% → 0.26% (+0.25%)
40% less funds holding
Funds holding: 15 → 9 (-6)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
+$157K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$114K |
| 3 |
Two Sigma Investments
New York
|
+$47.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$4.19K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Snowden Capital Advisors
New York
|
-$34K |
| 2 |
Bank of New York Mellon
New York
|
-$27K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$25K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$20K |
| 5 |
VF
Virtu Financial
New York
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $245K | +$114K | +1,414 | +56% |
|
|
2
Two Sigma Advisers
New York
| $121K | +$157K | +1,948 | New |
|
3
Geode Capital Management
Boston,
Massachusetts
| $43K | – | – | – |
|
|
4
Two Sigma Investments
New York
| $37K | +$47.4K | +589 | New |
|
|
5
UBS Group
Zurich,
Switzerland
| $14K | +$3.22K | +40 | +22% |
|
|
TRCT
6
Tower Research Capital (TRC)
New York
| $4K | +$4.19K | +52 | +289% |
|
|
SCA
7
Snowden Capital Advisors
New York
| – | -$34K | -407 | Closed |
|
|
8
Bank of New York Mellon
New York
| – | -$27K | -319 | Closed |
|
|
9
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| – | -$25K | -297 | Closed |
|
|
VF
10
Virtu Financial
New York
| – | -$20K | -234 | Closed |
|
|
11
Northern Trust
Chicago,
Illinois
| – | -$20K | -232 | Closed |
|
12
HighTower Advisors
Chicago,
Illinois
| – | -$14K | -163 | Closed |
|
|
SG
13
StoneX Group
New York
| – | -$4.75K | -56 | Closed |
|
14
State Street
Boston,
Massachusetts
| – | -$4K | -48 | Closed |
|
15
Wells Fargo
San Francisco,
California
| – | +$161 | +2 | +200% |
|
ARTL Hedge Fund Activity: Q3 2022 in Review
9 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2022, worth a combined $464K — up 4.8% from $443K a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of ARTL and 2 opened new positions — a net loss of 6 holders — while 0 trimmed existing stakes and 4 added.
The largest buyer was Two Sigma Advisers, opening a new position worth an estimated $157K. The largest seller was Snowden Capital Advisors, exiting entirely with an estimated $34K sold.
- 9 institutional investors held Artelo Biosciences (ARTL) as of Q3 2022, down from 15 in Q2 2022.
- Funds reported $464K of Artelo Biosciences stock for Q3 2022, up 4.8% quarter-over-quarter.
- 2 funds opened new Artelo Biosciences positions in Q3 2022 and 8 closed out, a net change of -6 holders.
- The largest Artelo Biosciences buyer in Q3 2022 was Two Sigma Advisers, an estimated $157K added.
- The largest Artelo Biosciences seller in Q3 2022 was Snowden Capital Advisors, an estimated $34K sold.
Based on aggregated 13F filings for Q3 2022.